{"id":40053,"date":"2025-08-26T11:27:57","date_gmt":"2025-08-26T03:27:57","guid":{"rendered":"https:\/\/flcube.com\/?p=40053"},"modified":"2025-08-26T11:27:58","modified_gmt":"2025-08-26T03:27:58","slug":"chengdu-ucellos-uc101-car%e2%80%91t-gains-nmpa-approval","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=40053","title":{"rendered":"Chengdu Ucello\u2019s UC101 CAR\u2011T Gains NMPA Approval"},"content":{"rendered":"\n

China\u2011based Chengdu Ucello Biotechnology Co., Ltd. announced that its Investigational New Drug (IND) application for UC101\u2014a self\u2011developed, off\u2011the\u2011shelf allogeneic CAR\u2011T injection targeting CD19\u2014has been officially approved by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA).<\/p>\n\n\n\n

What Makes UC101 a Game\u2011Changer<\/strong>
UC101 is derived from newborn cord blood and employs multi\u2011gene editing to create a stable, off\u2011the\u2011shelf product. The platform eliminates graft\u2011versus\u2011host disease (GvHD) and host\u2011versus\u2011graft rejection (HvGR) at the source, while delivering superior in\u2011vivo expansion and persistence compared with conventional CAR\u2011T therapies.<\/p>\n\n\n\n

Manufacturing Breakthroughs<\/strong>
UC101 is the world\u2019s first CAR\u2011T therapy produced from a stable cell line that generates lentiviral vectors, eliminating the need for plasmid raw materials. The streamlined process cuts manufacturing costs by more than 70\u202f%, and a single batch can serve over 100 patients.<\/p>\n\n\n\n

Early Clinical Success in B\u2011ALL<\/strong>
In investigator\u2011initiated trials for B\u2011cell acute lymphoblastic leukemia (B\u2011ALL), UC101 achieved a 90\u202f% complete remission rate with manageable adverse events. Key efficacy metrics outperformed comparable international products, underscoring the therapy\u2019s potent B\u2011cell\u2011clearing ability.<\/p>\n\n\n\n

Future Directions<\/strong>
Beyond B\u2011ALL, Chengdu Ucello plans exploratory studies of UC101 in autoimmune diseases, leveraging its robust B\u2011cell depletion profile. The NMPA clearance positions UC101 as a promising first\u2011in\u2011class CAR\u2011T candidate for both oncology and immune\u2011mediated disorders.<\/p>\n\n\n\n

Industry Impact<\/strong>
The approval of UC101 marks a significant milestone for China\u2019s burgeoning cellular therapy sector, demonstrating that off\u2011the\u2011shelf CAR\u2011T can be produced at scale, cost\u2011effective, and with an improved safety profile.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

China\u2011based Chengdu Ucello Biotechnology Co., Ltd. announced that its Investigational New Drug (IND) application for…<\/p>\n","protected":false},"author":1,"featured_media":40057,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[16,21,77,62,3136],"class_list":["post-40053","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-cancer","tag-car-t","tag-cell-therapy","tag-clinical-trial-approval-initiation","tag-ucello-biotechnology"],"yoast_head":"\nChengdu Ucello\u2019s UC101 CAR\u2011T Gains NMPA Approval - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China\u2011based Chengdu Ucello Biotechnology Co., Ltd. announced that its Investigational New Drug (IND) application for UC101\u2014a self\u2011developed, off\u2011the\u2011shelf allogeneic CAR\u2011T injection targeting CD19\u2014has been officially approved by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA).\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=40053\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Chengdu Ucello\u2019s UC101 CAR\u2011T Gains NMPA Approval\" \/>\n<meta property=\"og:description\" content=\"China\u2011based Chengdu Ucello Biotechnology Co., Ltd. announced that its Investigational New Drug (IND) application for UC101\u2014a self\u2011developed, off\u2011the\u2011shelf allogeneic CAR\u2011T injection targeting CD19\u2014has been officially approved by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA).\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=40053\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-08-26T03:27:57+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-08-26T03:27:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2603.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40053#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40053\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Chengdu Ucello\u2019s UC101 CAR\u2011T Gains NMPA Approval\",\"datePublished\":\"2025-08-26T03:27:57+00:00\",\"dateModified\":\"2025-08-26T03:27:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40053\"},\"wordCount\":286,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40053#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2603.webp\",\"keywords\":[\"Cancer\",\"CAR-T\",\"Cell-therapy\",\"Clinical trial approval \\\/ initiation\",\"Ucello Biotechnology\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=40053#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40053\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=40053\",\"name\":\"Chengdu Ucello\u2019s UC101 CAR\u2011T Gains NMPA Approval - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40053#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40053#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2603.webp\",\"datePublished\":\"2025-08-26T03:27:57+00:00\",\"dateModified\":\"2025-08-26T03:27:58+00:00\",\"description\":\"China\u2011based Chengdu Ucello Biotechnology Co., Ltd. announced that its Investigational New Drug (IND) application for UC101\u2014a self\u2011developed, off\u2011the\u2011shelf allogeneic CAR\u2011T injection targeting CD19\u2014has been officially approved by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA).\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40053#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=40053\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40053#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2603.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/08\\\/2603.webp\",\"width\":1080,\"height\":608,\"caption\":\"Chengdu Ucello\u2019s UC101 CAR\u2011T Gains NMPA Approval\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=40053#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Chengdu Ucello\u2019s UC101 CAR\u2011T Gains NMPA Approval\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Chengdu Ucello\u2019s UC101 CAR\u2011T Gains NMPA Approval - Insight, China's Pharmaceutical Industry","description":"China\u2011based Chengdu Ucello Biotechnology Co., Ltd. announced that its Investigational New Drug (IND) application for UC101\u2014a self\u2011developed, off\u2011the\u2011shelf allogeneic CAR\u2011T injection targeting CD19\u2014has been officially approved by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA).","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=40053","og_locale":"en_US","og_type":"article","og_title":"Chengdu Ucello\u2019s UC101 CAR\u2011T Gains NMPA Approval","og_description":"China\u2011based Chengdu Ucello Biotechnology Co., Ltd. announced that its Investigational New Drug (IND) application for UC101\u2014a self\u2011developed, off\u2011the\u2011shelf allogeneic CAR\u2011T injection targeting CD19\u2014has been officially approved by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA).","og_url":"https:\/\/flcube.com\/?p=40053","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-08-26T03:27:57+00:00","article_modified_time":"2025-08-26T03:27:58+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2603.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=40053#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=40053"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Chengdu Ucello\u2019s UC101 CAR\u2011T Gains NMPA Approval","datePublished":"2025-08-26T03:27:57+00:00","dateModified":"2025-08-26T03:27:58+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=40053"},"wordCount":286,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=40053#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2603.webp","keywords":["Cancer","CAR-T","Cell-therapy","Clinical trial approval \/ initiation","Ucello Biotechnology"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=40053#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=40053","url":"https:\/\/flcube.com\/?p=40053","name":"Chengdu Ucello\u2019s UC101 CAR\u2011T Gains NMPA Approval - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=40053#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=40053#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2603.webp","datePublished":"2025-08-26T03:27:57+00:00","dateModified":"2025-08-26T03:27:58+00:00","description":"China\u2011based Chengdu Ucello Biotechnology Co., Ltd. announced that its Investigational New Drug (IND) application for UC101\u2014a self\u2011developed, off\u2011the\u2011shelf allogeneic CAR\u2011T injection targeting CD19\u2014has been officially approved by the Center for Drug Evaluation (CDE) of the National Medical Products Administration (NMPA).","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=40053#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=40053"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=40053#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2603.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2603.webp","width":1080,"height":608,"caption":"Chengdu Ucello\u2019s UC101 CAR\u2011T Gains NMPA Approval"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=40053#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Chengdu Ucello\u2019s UC101 CAR\u2011T Gains NMPA Approval"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/08\/2603.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40053","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=40053"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40053\/revisions"}],"predecessor-version":[{"id":40058,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/40053\/revisions\/40058"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/40057"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=40053"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=40053"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=40053"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}